| Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein, W Verret, SP Hack, ... The Lancet Oncology 21 (6), 808-820, 2020 | 424 | 2020 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 212 | 2023 |
| Phase I study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors KH Jung, P LoRusso, H Burris, M Gordon, YJ Bang, MD Hellmann, ... Clinical Cancer Research 25 (11), 3220-3228, 2019 | 198 | 2019 |
| Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts A Capasso, J Lang, TM Pitts, KR Jordan, CH Lieu, SL Davis, JR Diamond, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 137 | 2019 |
| Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors TM Pitts, SL Davis, SG Eckhardt, EL Bradshaw-Pierce Pharmacology & therapeutics 142 (2), 258-269, 2014 | 110 | 2014 |
| A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic … SL Davis, DB Cardin, S Shahda, HJ Lenz, E Dotan, BH O’Neil, ... Investigational new drugs 38, 821-830, 2020 | 76 | 2020 |
| Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers SL Davis, SG Eckhardt, JJ Tentler, JR Diamond Therapeutic advances in medical oncology 6 (3), 88-100, 2014 | 56 | 2014 |
| Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers M Yarchoan, L Cope, AN Ruggieri, RA Anders, AM Noonan, LW Goff, ... The Journal of Clinical Investigation 131 (24), 2021 | 51 | 2021 |
| A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors. HA Burris, MS Gordon, MD Hellmann, P LoRusso, LA Emens, FS Hodi, ... Journal of Clinical Oncology 35 (15_suppl), 105-105, 2017 | 30 | 2017 |
| Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants LN Micel, JJ Tentler, AC Tan, HM Selby, KL Brunkow, KM Robertson, ... Molecular cancer therapeutics 14 (2), 317-325, 2015 | 30 | 2015 |
| Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer TM Pitts, EL Bradshaw, SM Bagby, SL Hyatt, HM Selby, A Spreafico, ... Oncotarget 7 (31), 50290, 2016 | 28 | 2016 |
| Phase Ib results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer A Krishnamurthy, A Dasari, AM Noonan, JM Mehnert, AC Lockhart, ... Cancer research 78 (18), 5398-5407, 2018 | 25 | 2018 |
| Association of cancer immunotherapy with acute macular neuroretinopathy and diffuse retinal venulitis LA Emens, SL Davis, SCN Oliver, CH Lieu, A Reddy, S Solomon, L He, ... JAMA ophthalmology 137 (1), 96-100, 2019 | 23 | 2019 |
| Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models SL Davis, KM Robertson, TM Pitts, JJ Tentler, EL Bradshaw-Pierce, ... Frontiers in pharmacology 6, 120, 2015 | 23 | 2015 |
| Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer SJ Zakem, AC Mueller, C Meguid, RJ Torphy, DE Holt, T Schefter, ... HPB 23 (7), 1072-1083, 2021 | 19 | 2021 |
| Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II … MJ Borad, LY Bai, MH Chen, JM Hubbard, K Mody, SY Rha, DA Richards, ... Journal of Clinical Oncology 39 (3_suppl), 312-312, 2021 | 19 | 2021 |
| Abstract CT043: A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental … M Yarchoan, L Cope, RA Anders, A Noonan, LW Goff, L Goyal, J Lacy, ... Cancer Research 80 (16_Supplement), CT043-CT043, 2020 | 19 | 2020 |
| Biomarkers to predict immune-related adverse events with checkpoint inhibitors. L Head, N Gorden, R Van Gulick, CM Amato, A Frazer-Abel, W Robinson, ... Journal of Clinical Oncology 37 (8_suppl), 131-131, 2019 | 19 | 2019 |
| Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. GT King, P Sharma, SL Davis, A Jimeno Drugs of Today (Barcelona, Spain: 1998) 54 (2), 103-122, 2018 | 18 | 2018 |
| WEE1 inhibition in combination with targeted agents and standard chemotherapy in preclinical models of pancreatic ductal adenocarcinoma SJ Hartman, SM Bagby, BW Yacob, DM Simmons, M MacBeth, CH Lieu, ... Frontiers in Oncology 11, 642328, 2021 | 16 | 2021 |
